Objective. To measure organizations' implementation of Chronic Care Model (CCM) interventions for chronic care quality improvement (QI). The...
Health Services Research, 08/01/05 by Marjorie L. Pearson · More from publicationYou’re doing the job of two, handling even crankier customers than usual, and worried you’ll never be able to retire. But now is not the time to blow a gasket.
The FDA has only two inspectors for medical products in China, the country to which much of the drug industry is moving its manufacturing and R&D facilities. The FDA confirmed the number at the request of BNET, following reports that Pfizer (PFE), AstraZeneca (AZN), Eli Lilly (LLY) and Novartis (NVS) were moving a variety of functions to the country.
In this economy, enticing offers abound. But a lot of so-called bargains may turn out to be raw deals.
